Clinical characteristics of patients (probands and their relatives) with either MODY, FDA or T2DM.

<p>Continuous variables were reported as mean <u>+</u> SD, whereas categorical variables are reported as percentages. FDA: Familial Diabetes of the Adulthood; MODY: Maturity Onset Diabetes of the Young; T2DM: Type 2 Diabetes Mellitus; HbA1c: Glycated hemoglobin; OADs: Oral Antidiabetes Drugs</p><p>*: p<0.001 vs. T2DM patients</p><p>^†: p≤0.01 vs. MODY patients</p><p>**: p<0.05 vs. T2DM patients</p><p>^††: p≤0.05 vs. MODY patients.</p><p>Because of the well-known differences across the two clinical entities, no comparisons were carried out between MODY and T2DM.</p><p>Clinical characteristics of patients (probands and their relatives) with either MODY, FDA or T2DM.</p

Scatterplot of age at diagnosis in adult patients with MODY, FDA and T2DM.

<p>Scatterplot of age at diagnosis in adult patients with MODY, FDA and T2DM.</p

Demographic and clinical characteristics of patients at baseline according to APOE genotype.

<p>Demographic and clinical characteristics of patients at baseline according to APOE genotype.</p

Hazard ratios for incident cardiovascular events.

<p>Hazard ratios for incident cardiovascular events.</p

Kaplan–Meier estimates of the adverse events according to genotype.

<p>A) Major adverse cardiac events (MACE), B) Total peripheral revascularizations, C) Total deaths.</p

Events at follow-up.

<p>Events at follow-up.</p